HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Anczak, J. D. Articles by Nogler, R. A. Search for Related Content PubMed PubMed Citation Articles by Anczak, J. D. Articles by Nogler, R. A., II

Tobacco Cessation in Primary Care: Maximizing Intervention Strategies

Orthopaedics, Marshfield Clinic-Eau Claire Center, Eau Claire, Wisconsin

Robert A. Nogler, MD, II

Family Practice, Marshfield Clinic-Ladysmith Center, Ladysmith, Wisconsin

REPRINT REQUESTS: John D. Anczak, PA-C, Marshfield Clinic-Eau Claire Center, 2116 Craig Road, Eau Claire, WI 54701, Telephone: 715-858-4650, Fax: 715-858-4501, Email: anczak.john{at}marshfieldclinic.org

[See related article 175 – 176]

The most effective preventive intervention that a clinician can provide for tobacco-using patients against heart disease, cancer, cerebrovascular disease and chronic obstructive pulmonary disease is an empathic, personalized smoking cessation intervention program with extended assistance and follow-up. The goal of the intervention must be complete smoking cessation. Reduction provides no direct health benefits to the individual smoker. Interventions are readily available, but underutilized, in part due to lack of clinician training and organizational support.

The present article summarizes the current guidelines for smoking cessation interventions as a framework from which to start. The guidelines incorporate the Transtheoretical Model of patient behavioral change and the "Five A’s": Ask, Advise, Assess, Assist and Arrange. Pharmacotherapeutic tools, including nicotine replacement therapies (nicotine gums, patches, nasal sprays, inhalers and new therapies) and non-nicotine therapies (bupropion, clonidine, nortriptyline and other antidepressants and anxiolytics) are considered. Adherence validation methods, new approaches to tobacco and addiction treatment that appear in the recent research literature are reviewed.

Beyond this framework, specific categories of tobacco users (including smokeless tobacco users), cultural and ethnic minorities, adolescents using snuff and bidis, women, Medicaid recipients, and users of multiple forms of tobacco require special consideration.

With this framework and the modifications that may be required for specific categories of patients, practicing clinicians can incorporate into daily practice a successful tobacco cessation intervention program with quit rates approaching 20%.

Key Words: Smoking cessation • Tobacco • Cigarettes • Smokeless tobacco • Bidis • Bupropion • Nicotine replacement therapy